Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29543900 | 1.00 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DTAAR1 | |
| SCHEMBL6946789 | 0.86 | HTR2C (0.47) | TAAR1HRH3HTR2CGAAKDM4E | |
| SCHEMBL6944731 | 0.84 | HTR2C (0.47) | HRH3HTR2CKMT2AL3MBTL1 | |
| SCHEMBL6946821 | 0.81 | PARP1 (0.38) | HTR2C | |
| SCHEMBL4237792 | 0.81 | MAPT (0.41) | HRH3ALDH1A1L3MBTL1 | |
| SCHEMBL10442246 | 0.80 | HTR2C (0.50) | TAAR1HTR2CHTR6GAAKDM4E | |
| SCHEMBL28320156 | 0.80 | HTR2C (0.54) | TAAR1HTR2CMEN1KMT2A | |
| SCHEMBL5493566 | 0.79 | HTR2C (0.35) | HTR2CGAAKDM4EALDH1A1GLA | |
| SCHEMBL29601297 | 0.79 | CYP3A4 (0.44) | GAAMEN1KMT2ANAMPT | |
| SCHEMBL5440110 | 0.78 | CYP1A2 (0.48) | ALDH1A1HPGDHSD17B10IP6K1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 928 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | claimed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | claimed |
| US-20180162898-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2018-06-14 | — | — | US | claimed |
| EP-1292603-B1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-22 | — | — | EP | claimed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | claimed |
| US-20160280729-A1 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-09-29 | — | — | US | claimed |
| WO-2015077360-A2 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-05-28 | — | — | WO | claimed |
| EP-2322518-B1 | Method of manufacture of 1,3-dioxolane and 1,3-oxathiolane nucleosides | GILEAD SCIENCES INC (US) | 2015-02-25 | — | — | EP | claimed |
| US-20140121186-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | CHIMERIX, INC. (US) | 2014-05-01 | — | — | US | claimed |
| US-20140113880-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | claimed |
| WO-2004046331-A2 | 2’-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-03 | — | — | WO | claimed |
| US-20040087806-A1 | Processes for preparing 1,3-dioxolane nucleosides | PHARMASSET, INC. | 2004-05-06 | — | — | US | claimed |
| WO-2004028445-A2 | PROCESSES FOR PREPARING 1,3-DIOXOLANE NUCLEOSIDES | PHARMASSET INC. (US) | 2004-04-08 | — | — | WO | claimed |
| US-6518425-B1 | A process for producing a 1,3-oxathiolane nucleoside comprising reacting a 5-halo-2-protected-oxymethyl-1,3-oxathiolane with a silylated purine or pyrimidine without the addition of a Lewis acid or an additional base to the reaction | EMORY UNIVERSITY | 2003-02-11 | — | — | US | claimed |
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | APOTEX PHARMACHEM INC (CA) | 2003-01-16 | — | — | US | claimed |
| EP-0562009-A4 | ENANTIOMERICALLY PURE -G(B)-D-(-)-DIOXOLANE-NUCLEOSIDES | — | 1993-11-24 | — | — | EP | claimed |
| EP-0562009-A1 | ENANTIOMERICALLY PURE $g(b)-D-(-)-DIOXOLANE-NUCLEOSIDES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1993-09-29 | — | — | EP | claimed |
| WO-1992010497-A1 | ENANTIOMERICALLY PURE β-D-(-)-DIOXOLANE-NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-06-25 | — | — | WO | claimed |
| WO-1992010496-A1 | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-06-25 | — | — | WO | claimed |
| US-4925901-A | STORAGE STAABILITY, ONIUM ION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1990-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121186-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | EYA3, EYA2, PDE6C | PDE4A 243/4885PDE4B 232/4885PDE4C 116/4885 |
| US-20160280729-A1 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | ZC3HAV1, HAVCR2, NSUN2 | PDE4A 1270/4885PDE4B 2128/4885PDE4C 2672/4885 |
| US-20040087806-A1 | Processes for preparing 1,3-dioxolane nucleosides | NUDT1, PNP, DPYD | PDE4A 406/4885PDE4B 349/4885PDE4C 420/4885 |
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | SLC29A1, NUDT1, SLC28A1 | PDE4A 883/4885PDE4B 1348/4885PDE4C 983/4885 |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | PDE4A 2185/4885PDE4B 2237/4885PDE4C 2664/4885 |
| US-20140113880-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, SLC29A2 | PDE4A 322/4885PDE4B 302/4885PDE4C 423/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | PDE4A 2130/4885PDE4B 2199/4885PDE4C 2614/4885 |
| US-20180162898-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | NSUN2, NSUN3, ZC3HAV1 | PDE4A 352/4885PDE4B 410/4885PDE4C 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.